Philip A. Pizzo, M.D.

Publication Details

  • Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine Jankelevich, S., Mueller, B. U., Mackall, C. L., Smith, S., Zwerski, S., Wood, L. V., Zeichner, S. L., Serchuck, L., STEINBERG, S. M., Nelson, R. P., Sleasman, J. W., Nguyen, B. Y., Pizzo, P. A., Yarchoan, R. OXFORD UNIV PRESS INC. 2001: 1116-1120


    Virologic and immunologic responses were examined for 33 human immunodeficiency virus (HIV)-infected children who participated for > or = 96 weeks in a phase 1/2 protocol of 16 weeks of indinavir monotherapy, followed by the addition of zidovudine and lamivudine. At week 96, a median increase of 199 CD4+ T cells/microL and a median decrease of 0.74 log(10) HIV RNA copies/mL were observed. The relationship between control of viral replication and CD4) T cell count was examined. Patients were categorized into 3 response groups on the basis of duration and extent of control of viral replication. Of 21 children with a transient decrease in virus load of > or = 0.7 log(10) HIV RNA copies/mL from baseline, 7 experienced sustained increases in CD4+, CD4+ CD45RA+, and CD4+ CD45RO+ T cell counts. CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression.

    View details for Web of Science ID 000167366900018

    View details for PubMedID 11237839

Stanford Medicine Resources:

Footer Links: